Advertisement
Document › Details
Laboratoris Sanifit S.L.. (7/17/18). "Press Release: Sanifit to Present at the 2018 European Biotech Investor Day in New York City". Palma & San Diego, CA.
Region | New York, NY | |
Country | United States (USA) | |
Organisation | Laboratoris Sanifit S. L. | |
Group | Vifor Pharma (Group) | |
Organisation 2 | Goodwin Procter LLP | |
Group | Goodwin Procter (Goowin Law) (Group) | |
Product | European Biotech Investor Day in NYC 2018 | |
Product 2 | SNF472 (Sanifit) | |
Index term | Sanifit–PNC Financial Services: investor conference, 201807 supply service Sanifit presents at 2018 European Biotech Investor Day in NYC | |
Person | Perelló, Joan (Sanifit 201509 CEO) | |
Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, will present at the European Biotech Investor Day in NYC, organized by Solebury Trout, Goodwin LLC and Nasdaq.
Sanifit will present at 3.00 PM on Thursday, July 19. Dr Joan Perelló, CEO at Sanifit, will discuss the company’s clinical progress and financing plans for the continued development of SNF472 for the treatment of calciphylaxis and cardiovascular disease in patients suffering from end stage kidney disease and undergoing dialysis.
The European Biotech Investor Day in NYC, features privately-held and EU-listed biotechnology companies representing the “Next Wave of Opportunities” emerging from Europe. The life science – focused conference will be held at Goodwin LLC offices in the New York Times building.
For media enquiries:
Sanifit
Antonio Jiménez, VP Operations
Email: info@sanifit.com
About SNF472
SNF472 is an intravenous formulation of myo-inositol hexaphosphate with a novel mechanism of action for the treatment of haemodialysis patients with cardiovascular diseases linked to calcification. SNF472 is being developed for two indications: calciphylaxis and cardiovascular disease in end stage renal disease (CV-ESRD) patients undergoing dialysis. SNF472 has orphan drug status for the treatment of calciphylaxis from both the EMA and FDA. SNF472 selectively blocks the progression of pathological cardiovascular calcification, and poses an innovative solution for these unmet medical needs.
About Sanifit
Sanifit is a biopharmaceutical company focused on calcification disorders. The company was founded in 2007 as a spin-off of the University of the Balearic Islands and expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, with a Phase 3 pivotal study planned to initiate in 2H 2018. The company is also investigating SNF472 in a Phase 2b study in CV-ESRD, with results expected in Q4 2019. Sanifit has raised more than $50M, including a series C funding of $41.3M (€36.6M) in mid-2015. For more information please visit www.sanifit.com
Record changed: 2023-06-05 |
Advertisement
More documents for Vifor Pharma (Group)
- [1] T-Knife Therapeutics, Inc.. (1/5/22). "Press Release: T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel". South San Francisco, CA & Paris....
- [2] Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen....
- [3] Vifor Pharma AG. (11/09/20). "Press Release: Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications". St. Gallen & Uniondale, NY....
- [4] Vifor Pharma AG. (10/20/20). "Press Release: Vifor Pharma and Cara Therapeutics Sign US License Agreement for i.v. Korsuva to Treat Dialysis Patients with Pruritus". St. Gallen & Stamford, CT....
- [5] ChemoCentryx Inc.. (11/25/19). "Press Release: ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis". Mountain View, CA & St...
- [6] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
- [7] Vifor Pharma AG. (5/23/18). "Press Release: VFMCRP and Cara Therapeutics to Develop and Commercialise CR845 Injection for Chronic Kidney Disease-associated Pruritus"....
- [8] Actimed Therapeutics Ltd.. (4/5/18). "Press Release: Actimed Therapeutics Appoints Pharma Veteran Dr David Ebsworth as Chairman". Ascot....
- [9] Laboratoris Sanifit S.L.. (3/6/18). "Press Release: Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis". Palma & San Diego, CA....
- [10] Laboratoris Sanifit S.L.. (1/8/18). "Press Release: Sanifit Announces the Appointment of Cris Calsada as Chief Financial Officer". Palma & San Diego, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top